Urigen's pipeline includes URG101, targeting the treatment of painful bladder syndrome (PBS), symptoms of pelvic bladder syndrome secondary to pelvic irradiation and dyspareunia; URG301, targeting acute urgency in patients diagnosed with overactive bladder, acute urethral discomfort and urethritis; and URG302, a follow-on program targeting acute urgency in patients diagnosed with overactive bladder.
View the product pipeline

Jun 5, 2008, 10:10am PST - Live Webcast - Urigen presents at RedChip Small Cap Investors Conference. Click here to view the recorded webcast:
http://www.modavox.com/events/redchip/0608/ssafe/login/login.html

Dec 29 2008 - Urigen Amends Its Core UCSD License for URG101

Nov 5 2008 - Urigen Outlines Operating Plans

Aug 19 2008 - Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis

Jun 4 2008 - Urigen to Present At RedChip Small-Cap Investor Conference

Apr 25 2008 - Urigen Announces US Patent Office Notice of Allowance of Claims for URG101

Apr 9 2008 - FDANews: Urigen Candidate Demonstrates Positive Results in Trial

Apr 7 2008 - Urigen Announces Early Closure of URG101 Phase II Clinical Trial based on Positive Interim Analysis Results

Mar 12 2008 - Urigen Announces Positive Phase II Clinical Trial Results with URG101
Archives

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications. Urigen has two primary programs in development that are either in or positioned to enter Phase II clinical trials.